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petownership_stats.htm), and many pets are just as
important as a family member or friend, sometimes
more; for them, the same level of health care is
expected. Cost of treatment and subsequent quality of
life is an issue for the care of animals and humans.
Doctors may not fully appreciate the importance of
the relationship between owners and their animals.
This may be relevant when, for example, advising
immunocompromised patients of any risk from their
pets, or considering the implications of taking an
elderly pet owner into care in an environment where
animals are banned. When advising patients about
owning pets, doctors now have to weigh up the risks of
developing allergies.2
The BMJ and the Veterinary Record plan simultane-
ous publication of theme issues exploring how the two
professions can collaborate for mutual benefit. We
would like to cover topics such as the investigation and
control of infectious diseases; zoonoses; medical and
veterinary education; professional regulation; and
issues related to pet ownership. The theme issues, to be
published in November 2005, will be a mix of papers,
debate pieces, editorials, and reviews. We are particu-
larly interested in original research relevant to both
disciplines. The deadline for submissions of original
research is 30 May 2005.
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Treatment of postmenopausal osteoporosis
Has improved owing to the availability of many drugs that prevent fractures
Osteoporosis is characterised by bone fragilitydue to low bone mass and modifications ofthe internal bone structure, with alterations
of its microarchitecture. Of various fragility fractures
that represent the major complication of the disease,
vertebral and hip fractures are associated with
pronounced morbidity and increased mortality.1
Several agents have been used for many years to
prevent or treat osteoporosis. However, methodologi-
cally sound randomised controlled trials assessing
their efficacy against fractures at the axial (vertebral)
and appendicular (non-vertebral) sites have become
available only in the last 15 years. Most of these trials
were recently summarised in systematic reviews.1–3
Bisphosphonates are potent inhibitors of resorp-
tion and represent 70% of the worldwide market for
drugs used to treat osteoporosis. Alendronate and
risedronate were both investigated in well designed,
randomised controlled trials, where their ability to
reduce vertebral, non-vertebral, and hip fractures was
shown—the latter mainly in women with severe
osteoporosis (low bone density and prevalent
fractures).2–6 Both are widely available as daily or weekly
oral formulations. No head to head comparisons
between alendronate and risedronate have been made.
Results of published randomised controlled trials or
meta-analysis do not provide compelling evidence for
statistically significant differences in their efficacy or
safety. Both compare favourably with etidronate, the
first bisphosphonate developed, which in the absence
of an unequivocal effect on non-vertebral fractures
seems outdated. Ibandronate reduces vertebral
fractures, but its effect on non-vertebral fractures has
so far only been shown in a post hoc analysis
performed on a high risk subgroup.7
Selective oestrogen receptor modulators act as
oestrogen agonists or antagonists depending on the
target tissue. Raloxifene reduces vertebral fractures
across different degrees of skeletal fragility, ranging
from low bone density to severe osteoporosis,8 but little
evidence of efficacy in preventing non-vertebral
fractures is currently available.3 4 8 Major non-skeletal
benefits have been documented (in breast cancer) or
are under investigation (cardiovascular disease) and
should be considered when assessing the overall risk
to benefit ratio of selective oestrogen receptor
modulators.
The efficacy of hormone replacement therapy
against fractures has been derived mainly from
case-control and cohort studies.2 Although not
conducted in women included on the basis of an
increased risk of skeletal fragility, the women’s health
initiative trial,9 a randomised controlled trial designed
to assess the major health benefits and risks of the most
commonly used hormone replacement therapy in the
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bral and all fractures. However, when considering the
effects of hormone replacement therapy on all disease
outcomes in a global model, the authors concluded
that there was no net benefit even in women
considered to be at the highest risk of fracture.
Hormone replacement should be considered only in
women experiencing climacteric symptoms, for the
shortest possible duration, and with the lowest effective
doses.
Teriparatide, a parathormone, predominantly
stimulates bone formation when given intermittently.
A randomised controlled trial conducted in women
with severe osteoporosis showed reduction in vertebral
and all non-vertebral (but not hip) fractures.10 Since no
data are available in less severely affected women, the
use of parathormone should be limited to this particu-
lar population.
Strontium ranelate is a new chemical that inhibits
bone resorption and concomitantly stimulates bone
formation. Two large randomised controlled trials have
shown the ability of strontium ranelate to reduce verte-
bral and non-vertebral fractures in women with low
bone density with or without prevalent fractures. A
reduction of hip fractures has also been documented
in older women with very low bone density.11 12
Besides all these pharmacological agents, calcium
and vitamin D should be a first line strategy for the
management of osteoporosis. In view of the very low
mean dietary intake of calcium in most developed and
developing countries, a systematic pharmacological
supplementation in postmenopausal women seems to
be an appropriate strategy—unless an individual’s
dietary assessment shows a satisfactory intake. The
high prevalence of vitamin D deficiency in older
people (independently of the level of daylight or
sunshine exposure of their country) combined with the
low marginal cost of calcium and vitamin D
supplementation compared with calcium supplemen-
tation alone indicate that after the age of 65, calcium
and vitamin D should be offered to all postmenopausal
women, either alone or, if needed, with another thera-
peutic regimen.
The management of osteoporosis has improved in
the past 10 years with the availability of new drugs with
proved efficacy against fractures. In daily practice, the
decision to select a particular therapeutic option will
depend on the stage of the disease and the respective
risk of vertebral and non-vertebral fractures. It will also
take into account the documented skeletal and
non-skeletal benefits of the medication. What we need
now is research to assess the cost effectiveness of the
various medications in every clinical condition.
Jean-Yves Reginster director
Bone and Cartilage Metabolism Research Unit, CHU Centre-Ville,
Policliniques L. Brull, Quai Godefroid Kurth 45 (9ème étage),
4020 Liège, Belgium
(jyreginster@ulg.ac.be)
Competing interests: None declared.
1 Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;
359:2018-26.
2 Body JJ, Boonen S, Boutsen Y, De Vogelaer JP, Goemaere S, Kaufman JM,
et al. Evidence-based guidelines for the treatment of postmenopausal
osteoporosis: an updated consensus of the Belgian Bone Club. Osteoporos
Int 2005 (in press).
3 Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, et al. IX:
Summary of meta-analyses of therapies for postmenopausal osteoporo-
sis. Endocrine Rev 2002;23:570-8.
4 Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt
MC, et al. Randomised trial of effect of alendronate on risk of fracture in
women with existing vertebral fractures. Lancet 1996;348:1535-41.
5 McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al.
Hip intervention program study group: effect of risedronate on the risk
of hip fracture in elderly women. Hip Intervention Program Study
Group. N Engl J Med 2001;344:333-40.
6 Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML,
et al. Randomized trial of the effects of risedronate on vertebral fractures
in women with established postmenopausal osteoporosis. Vertebral Effi-
cacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int
2000;11:83-91.
7 Chesnut III CH, Skag A,Christiansen C, Recker R, Stakkestad JA,Hoiseth
A, et al. Effects of oral ibandronate administered daily or intermittently
on fracture risk in postmenopausal osteoporosis. J Bone Miner Res
2004;19:1241-9
8 Ettinger B, Black DM,Mitlak BH, Knickerbocker RK, Nickelsen T, Genant
HK, et al. Reduction of vertebral fracture risk in postmenopausal women
with osteoporosis treated with raloxifene: results from a 3-year
randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation
(MORE) Investigators. JAMA 1999;282:637-45.
9 Writing Group for the Women’s Health Initiative Investigators. Risks and
benefits of estrogen plus progestin in healthy postmenopausal women:
principal results from the women’s health initiative randomized control-
led trial. JAMA 2002;288:321-33.
10 Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et
al. Effect of parathyroid hormone (1-34) on fractures and bone mineral
density in postmenopausal women with osteoporosis. N Engl J Med
2001;344:1434-41.
11 Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector T, et al.
The effects of strontium ranelate on the risk of vertebral fracture in
women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-
68.
12 Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phene-
kos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures
in post-menopausal women with osteoporosis: TROPOS study. J Clin
Endocrinol Metab 2005 (in press).
Editorials
860 BMJ VOLUME 330 16 APRIL 2005 bmj.com
